| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAGEA3 |
| Uniprot No | P43357 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-314aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMPLEQRSQHCKPEEGLEARGEALGLVG AQAPATEEQEAASSSSTLVEVTLGEVPAAESPDPPQSPQGASSLPTTMNY PLWSQSYEDSSNQEEEGPSTFPDLESEFQAALSRKVAELVHFLLLKYRAR EPVTKAEMLGSVVGNWQYFFPVIFSKASSSLQLVFGIELMEVDPIGHLYI FATCLGLSYDGLLGDNQIMPKAGLLIIVLAIIAREGDCAPEEKIWEELSV LEVFEGREDSILGDPKKLLTQHFVQENYLEYRQVPGSDPACYEFLWGPRA LVETSYVKVLHHMVKISGGPHISYPPLHEWVLREGEE |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
nan
**Background of MAGEA3 Recombinant Protein**
The melanoma-associated antigen A3 (MAGEA3) is a member of the MAGE family of proteins, encoded by genes located on the X chromosome. These proteins are classified as cancer-testis antigens (CTAs) due to their restricted expression in normal tissues (primarily immune-privileged sites like testes and placenta) and frequent re-expression in various cancers, including melanoma, lung, and head and neck carcinomas. MAGEA3 is of significant interest in oncology due to its tumor-specific expression, making it a potential target for immunotherapy.
Recombinant MAGEA3 protein is produced using genetic engineering techniques, often expressed in bacterial or eukaryotic systems to ensure proper folding and post-translational modifications. Structurally, MAGEA3 contains a conserved MAGE homology domain implicated in protein-protein interactions, potentially regulating pathways like apoptosis, cell cycle progression, or ubiquitination. Its role in cancer remains partially unclear, though it may contribute to tumor survival by inhibiting apoptosis or promoting proliferation.
In therapeutic contexts, MAGEA3 has been explored as an antigen for cancer vaccines and adoptive T-cell therapies. Clinical trials have tested MAGEA3-directed vaccines in melanoma and non-small cell lung cancer (NSCLC), with mixed outcomes. While some studies showed immune activation and partial clinical responses, others faced challenges, including antigen loss, immune evasion, or limited efficacy in advanced tumors. These hurdles highlight the complexity of targeting CTAs and the need for combinatorial approaches.
Research also investigates MAGEA3's diagnostic potential, as its presence in tumors or circulation may correlate with disease progression. However, safety concerns persist due to low-level expression in some normal tissues, raising risks of off-target immune reactions. Despite setbacks, MAGEA3 remains a compelling candidate for precision oncology, underscoring the importance of biomarker-driven strategies to enhance therapeutic specificity and patient outcomes.
×
